Profile data is unavailable for this security.
About the company
Coloplast A/S is a Denmark-based company active within the healthcare sector. It is engaged in the development, marketing and sale of intimate healthcare products and services, targeting people with diseases of private and personal nature. Its operations are structured into four business areas: Ostomy Care offering products for people whose intestinal outlet has been rerouted through the abdominal wall, Continence Care products for people suffering from diseases of and damage to the urinary system, Urology Care products for people suffering from diseases of and damage to the kidneys, the urinary system or the male reproductive system and Wound & Skin Care for the treatment of chronic wounds and skin care products for prevention and treatment. The Company supplies products to hospitals, institutions as well as wholesalers and pharmacies.
- Revenue in DKK (TTM)27.89bn
- Net income in DKK3.99bn
- Incorporated1957
- Employees16.98k
- LocationColoplast A/SHoltedam 1-3HUMLEBAEK 3050DenmarkDNK
- Phone+45 49111111
- Fax+45 49111555
- Websitehttps://www.coloplast.dk/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioMerieux SA | 30.79bn | 2.82bn | 82.01bn | 14.75k | 29.19 | 2.78 | 12.85 | 2.66 | 3.18 | 3.18 | 34.66 | 33.32 | 0.7715 | 1.81 | 5.96 | 279,368.30 | 6.94 | 9.22 | 8.56 | 11.94 | 56.27 | 56.58 | 8.99 | 12.35 | 1.30 | 43.19 | 0.1139 | 20.24 | 8.31 | 8.27 | 20.86 | 9.64 | 4.88 | 36.49 |
| Smith & Nephew plc | 37.42bn | 3.09bn | 96.54bn | 17.00k | 32.32 | 2.86 | 13.50 | 2.58 | 0.4091 | 0.4091 | 4.95 | 4.63 | 0.5599 | 0.7184 | 4.26 | 251,036.30 | 4.62 | 3.62 | 5.48 | 4.41 | 70.04 | 70.47 | 8.26 | 7.10 | 1.40 | 7.24 | 0.3842 | 87.54 | 4.70 | 2.49 | 56.65 | -7.24 | -1.36 | -2.01 |
| Sonova Holding AG | 31.55bn | 4.27bn | 96.75bn | 18.04k | 22.72 | 4.86 | 15.28 | 3.07 | 8.71 | 8.71 | 64.41 | 40.72 | 0.7019 | 2.42 | 7.21 | 213,874.40 | 9.62 | 10.74 | 12.57 | 13.66 | 71.66 | 72.16 | 13.71 | 17.50 | 0.9087 | 16.87 | 0.377 | 42.61 | 6.58 | 5.79 | -10.07 | 5.22 | 1.33 | -- |
| Coloplast A/S | 27.89bn | 3.99bn | 102.70bn | 16.98k | 27.59 | 7.98 | 18.81 | 3.68 | 17.71 | 17.71 | 123.79 | 61.25 | 0.5743 | 2.38 | 6.12 | 1,625,729.00 | 8.21 | 12.75 | 10.44 | 17.10 | 67.87 | 67.86 | 14.30 | 18.95 | 0.8122 | 9.75 | 0.6451 | 100.37 | 3.12 | 8.49 | -28.03 | -2.83 | 8.92 | 5.02 |
| Sartorius AG | 26.27bn | 998.76m | 115.84bn | 13.88k | 94.53 | 4.74 | 24.31 | 4.41 | 1.94 | 1.94 | 51.09 | 38.65 | 0.3625 | 2.22 | 11.51 | 260,001.50 | 2.16 | 6.19 | 2.91 | 8.65 | 46.48 | 49.69 | 5.95 | 12.35 | 0.4922 | 2.89 | 0.5282 | 22.30 | -0.4417 | 13.10 | -59.14 | -11.72 | 12.69 | 15.84 |
| Sartorius Stedim Biotech SA | 22.01bn | 1.97bn | 127.20bn | 10.13k | 64.77 | 4.22 | 29.36 | 5.78 | 2.70 | 2.70 | 30.14 | 41.48 | 0.3712 | 2.18 | 11.69 | 297,606.30 | 3.34 | 8.62 | 3.86 | 10.54 | 45.64 | 49.34 | 9.00 | 15.34 | 0.5024 | 3.80 | 0.3863 | 20.94 | 0.1621 | 14.05 | -43.57 | -5.67 | 20.10 | 15.21 |
| Straumann Holding AG | 21.14bn | 3.51bn | 127.34bn | 11.95k | 36.34 | 7.55 | 26.64 | 6.02 | 2.68 | 2.47 | 16.15 | 12.90 | 0.7378 | 1.72 | 4.23 | 218,270.60 | 12.29 | 12.06 | 16.00 | 15.54 | 71.24 | 74.11 | 16.65 | 17.39 | 1.13 | 10.42 | 0.1743 | 32.23 | 9.98 | 9.42 | 2.11 | 8.35 | 2.28 | 10.56 |
| Holder | Shares | % Held |
|---|---|---|
| Fundsmith LLPas of 06 Feb 2026 | 7.68m | 3.65% |
| Flossbach von Storch SEas of 28 Nov 2025 | 6.18m | 2.94% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 5.25m | 2.50% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 2.77m | 1.32% |
| Comgest SAas of 31 Dec 2025 | 2.46m | 1.17% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 2.43m | 1.16% |
| Handelsbanken Fonder ABas of 31 Jan 2026 | 1.85m | 0.88% |
| Walter Scott & Partners Ltd.as of 11 Feb 2026 | 1.67m | 0.79% |
| Geode Capital Management LLCas of 12 Feb 2026 | 1.44m | 0.69% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 1.33m | 0.63% |
